Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06441318
Status:
COMPLETED
Last Update Posted:
2024-06-13
First Post:
2024-05-29
Brief Title:
A Study to Evaluate the Effect of Povorcitinib on the QTQTc Interval in Healthy Participants
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Study Overview
Official Title:
A Phase 1 Randomized Partially Double-Blind Placebo- and Positive-Controlled Parallel Study to Evaluate the Effect of Povorcitinib on the QTQTc Interval in Healthy Participants
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effect of povorcitinib on the QTQTc Interval in healthy participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None